Refine by
Breast Test Equipment & Supplies
6 equipment items found
Manufactured by:Menssana Research Inc. based inEdgewater, NEW JERSEY (USA)
It takes 300 screening mammograms to discover one woman with breast cancer. A breath test might improve this very low yield. Researchers have known for many years that women with breast cancer have abnormal volatile organic compounds (VOCs) in their breath. Clinical studies at Menssana Research have shown that these breath VOCs can accurately ...
Manufactured by:Metaltronica S.p.A. based inPomezia (Rm), ITALY
FIRST IN CLASS INNOVATIVE MOBILE MAMMOGRAPHY CLINIC FOR ALL BREAST SCREENING PROGRAMS. An all-in-one solution, now available in your neighborhood. 3D MAMMOGRAPHY BREAST, ULTRASOUND TESTING, ISTANT REPORTING. We believe life-saving early detection services should be available to every woman, everywhere. ...
Manufactured by:Cellanyx, LLC based inBeverly, MASSACHUSETTS (USA)
Risk stratification of early-stage breast cancer is an active area of research and several commercially available products that are based on genotypic classification. A vexing issue in breast cancer is carcinoma in situ – which has no metastatic potential. There are two sub types – Ductal Carcinoma in Situ (DCIS) and Lobular Carcinoma in Situ (LCIS). The incidence of these entities is ...
Manufactured by:INOVIQ Ltd based inNotting Hill, AUSTRALIA
INOVIQ has three autoantibody tests in development for early detection of ovarian, breast and lung cancers. BARD1 autoantibody tests measure autoantibodies to variant BARD1 proteins in the blood and use a proprietary cancer-specific algorithm to combine these levels into a cancer score that identifies the presence or absence of a specific cancer. ...
by:OncoStem Diagnostics Pvt. Ltd. based inBengaluru, INDIA
CanAssist Breast is a prognostic test developed by OncoStem that classifies the patients as ‘low-risk’ or ‘high-risk’ based on the patient’s risk of breast cancer recurrence over five years. CanAssist Breast provides information about the risk of recurrence of early-stage, hormone ...
Manufactured by:BioMark Diagnostics Inc. based inRichmond, BRITISH COLUMBIA (CANADA)
BioMark’s initial liquid biopsy assay detects SSAT1 using an FDA approved drug. SSAT1 is an enzyme with elevated levels in numerous cancers. The assay targets a well researched and understood metabolic pathway. BioMark of a few unique companies using safe therapeutic agents for diagnostic indication. As a non-invasive cost effective red alert tool, it is valuable to physicians around the ...